EQR
59
5
COST
63
5
KIM
76
2
AMG
52
2
JPM
67
4
AVY
50
2
RHI
57
3
PAYX
51
4
PCAR
56
3
XYL
45
8
FE
52
3
NSC
57
7
MTCH
42
5
SO
57
2
IVZ
48
2
LRCX
45
6
COP
54
-2
HSIC
51
-3
AVB
64
4
PH
73
3
EQR
59
5
COST
63
5
KIM
76
2
AMG
52
2
JPM
67
4
AVY
50
2
RHI
57
3
PAYX
51
4
PCAR
56
3
XYL
45
8
FE
52
3
NSC
57
7
MTCH
42
5
SO
57
2
IVZ
48
2
LRCX
45
6
COP
54
-2
HSIC
51
-3
AVB
64
4
PH
73
3
Financhill
Back

Essilorluxottica 10K Form

Buy
60

ESLOF
Essilorluxottica

Last Price:
240.50
Seasonality Move:
1.38%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ESLOF News And Ratings

See the #1 stock for the next 7 days that we like better than ESLOF

ESLOF Financial Statistics

Sales & Book Value

Annual Sales: $27.49B
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $91.50
Price / Book: 0

Profitability

EPS (TTM): 5.39340
Net Income (TTM): $2.48B
Gross Margin: $17.37B
Return on Equity: 5.93%
Return on Assets: 3.78%

Essilorluxottica Earnings Forecast

Key Essilorluxottica Financial Ratios

  • The Gross Profit Margin over the past 23 years for ESLOF is 63.19%.
  • The Selling, General & Administrative Expenses for ESLOF have been equal to 47.45% of Gross Profit Margin.
  • The Research & Development expenses have been 2.34% of Revenue.
  • The Interest Expense is 8.65% of Operating Income.
  • The Net Earning history of ESLOF is 9.01% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 17 years.

Essilorluxottica Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: ESLOF
Website: essilorluxottica.com

Debt

Debt-to-Equity Ratio: 0.22
Current Ratio: 1
Quick Ratio: 0.62

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ESLOF Technical Analysis vs Fundamental Analysis

Buy
60
Essilorluxottica (ESLOF) is a Buy

Is Essilorluxottica a Buy or a Sell?

  • Essilorluxottica stock is rated a Buy
    The current Essilorluxottica [ESLOF] share price is $246.35. The Score for ESLOF is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.